Tetraphase Pharmaceuticals (TTPH) PT Raised to $13 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
July 25, 2017 4:01 PM EDTÂ Â IV Eravacycline Achieves Primary Endpoint in Second of Two Pivotal Trials in cIAIÂ
  Company Proceeding with Regulatory Submissions in Europe in 3Q 2017 and U.S. in 1Q 2018  Â
  Ongoing Phase 3 IGNITE3 Clinical Trial in cUTI Expected to Complete Enrollment Early 4Q 2017 Â
  Conference Call Scheduled for Today at 5:00 p.m. ET Â
WATERTOWN, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:... More
